ReviewLeukemia2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Review in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives.Journal of hematology & oncology · 2026Review
- CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma.Blood advances · 2026Article
- Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.Blood advances · 2026Article
- Review
- A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.Blood cancer journal · 2026Article
- REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.Haematologica · 2026Observational
- BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.Advances in therapy · 2026Article
- The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies.Advances in therapy · 2026Article
- Engineering Soluble Recombinant BCMA for Ide-Cel Labeling.European journal of immunology · 2026Article
- Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.Bone marrow transplantation · 2026Article
- Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.Current oncology (Toronto, Ont.) · 2026Article
- Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.European journal of haematology · 2026Article
- Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.Journal of hematology & oncology · 2026Article
- Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.Cancers · 2026Review
- FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA.Advances in therapy · 2026Article
- Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT.Bone marrow transplantation · 2026Article
- Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.Leukemia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.